RIGEL PHARMACEUTICALS INC (RIGL): M&A transaction — Rigel closes VEPPANU license with Arvinas/Pfizer; pays $70M upfront

RIGEL PHARMACEUTICALS INC

Rigel gains exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant).
One-time upfront payment of $70 million made to Arvinas Inc., Arvinas Operations, Arvinas Estrogen Receptor, and Pfizer.
License agreement previously disclosed on May 12, 2026; HSR waiting period terminated early.
No additional upfront or milestone payment details provided beyond the $70 million.

item 2.01

Featured in Daily 8-K Digest

Selected #4 for 2026-06-17. Read digest

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

RIGEL PHARMACEUTICALS INC completed an acquisition involving Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. for $70.0 million.

Action: acquisition
Counterparty: Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.
Consideration: $70.0 million

Exact text from the filing

Following the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the satisfaction of the other closing conditions under the License Agreement, the License Agreement became effective and the transactions contemplated thereby were completed. In connection therewith, the Company paid the Licensors a one-time upfront payment of $70.0 million.

View on SEC.gov

82 m&a transactions filed in the last 30 days. Browse all m&a transactions →

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001034842-26-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.